Lilly's Zepbound Boosts Taltz Response in Psoriasis Study
Lilly reports Zepbound (tirzepatide) enhanced Taltz (ixekizumab) efficacy in a psoriasis study, a signal for combination therapy in metabolic-psoriatic disease.
Topic
Ixekizumab
Topic
Ixekizumab
Lilly Reports Taltz-Zepbound Combo Beats Taltz Alone in Psoriasis Study
Eli Lilly says a psoriasis study found Taltz plus Zepbound outperformed Taltz monotherapy; full efficacy and safety data are stil…
Ixekizumab–Tirzepatide Pair Moves Biomarkers in Psoriatic Obesity
Dermatology Times: ixekizumab plus tirzepatide shifted biomarkers in psoriasis patients with obesity. Detailed PASI, inflammatory…
Italian Multicenter Study Assesses Ixekizumab in Psoriatic Arthritis
Italian centers publish a multicentric retrospective observational study of ixekizumab in psoriatic arthritis, adding real-world…